ProQR Therapeutics NV
NASDAQ:PRQR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
NL |
|
TELA Bio Inc
NASDAQ:TELA
|
US |
|
A
|
Arizon RFID Technology Cayman Co Ltd
TWSE:6863
|
KY |
|
UniCredit SpA
MIL:UCG
|
IT |
|
Grand Canyon Education Inc
NASDAQ:LOPE
|
US |
|
Centene Corp
NYSE:CNC
|
US |
|
FILA Fabbrica Italiana Lapis ed Affini SpA
MIL:FILA
|
IT |
|
Nikkon Holdings Co Ltd
TSE:9072
|
JP |
|
Asahi Kasei Corp
TSE:3407
|
JP |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
US |
|
Birkenstock Holding PLC
NYSE:BIRK
|
UK |
|
Adidas AG
XETRA:ADS
|
DE |
|
China Overseas Land & Investment Ltd
HKEX:688
|
HK |
|
Banca Mediolanum SpA
MIL:BMED
|
IT |
|
Atea Pharmaceuticals Inc
NASDAQ:AVIR
|
US |
|
Mulberry Group PLC
LSE:MUL
|
UK |
Wall St Price Targets
PRQR Price Targets Summary
ProQR Therapeutics NV
According to Wall Street analysts, the average 1-year price target for
PRQR is 9.18 USD with a low forecast of 4.04 USD and a high forecast of 14.7 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is PRQR's stock price target?
Price Target
9.18
USD
According to Wall Street analysts, the average 1-year price target for
PRQR is 9.18 USD with a low forecast of 4.04 USD and a high forecast of 14.7 USD.
What is the Revenue forecast for ProQR Therapeutics NV?
Projected CAGR
55%
Over the last 12 years, the compound annual growth rate for Revenue has been 51%. The projected CAGR for the next 8 years is 55%.